S tudies of the maintenance of self-tolerance and the mechanisms by which this tolerance can be broken are essential to an understanding of the pathogenesis of autoimmune diseases. Central tolerance plays an important role deleting selfreactive T cells in the thymus (1) (2) (3) . Yet autoreactive T cells do exist in the peripheral repertoire. This may be due to either incomplete negative selection of T cells in the thymus (1) (2) (3) (4) or to the inherently cross-reactive nature of TCRs (5, 6) . Several mechanisms of peripheral tolerance that prevent the activation of these autoreactive T cells have been proposed. In addition to the role of regulatory/suppressor T cell populations, ignorance of self-Ags (7, 8) , down-regulation of the TCR or coreceptors (9 -11) , and the complete elimination of autoreactive T cell clones from the peripheral repertoire (12) (13) (14) can result in tolerance against self. Functional unresponsiveness of T cells, i.e., anergy, is another potential mechanism to silence self-reactive T cells. Although anergy was originally defined as a defect in TCR-dependent proliferation and production of IL-2 in vitro (15) (16) (17) , this form of T cell unresponsiveness has been demonstrated in several in vivo models as well (18 -26) .
In the face of activation these mechanisms of peripheral tolerance can fail, and cross-reactive foreign Ag can induce a detrimental T cell response that leads to autoimmune disease (27, 28) . Because T cells expressing a high-affinity TCR to self-Ags are deleted in the thymus by negative selection, cross-reactive foreign Ags can activate low-affinity self-reactive T cells; however, the conditions and mechanisms by which cross-reactive non-self-Ags break self-tolerance and induce autoimmunity have not been elucidated. Memory T cells have a lower threshold for activation; thus, when activated during an immune response against highaffinity foreign Ags, cross-reactive low-affinity self-ligands may potentially reactivate an autoreactive T cell response. We have recently proposed a mechanism which can counteract this crossreactive memory T cell response. Using a TCR transgenic (tg) 5 mouse model, we showed that stimulation of T cells with a superagonist ligand, L144, tuned the T cells and this resulted in nonresponsiveness rather than hyperresponsiveness to the self-ligand (29) . This mechanism may contribute to the maintenance of peripheral tolerance, where self-peptides fail to induce deletion, possibly due to their low affinity for the TCR or to the poor expression of self-Ag in the thymus.
In contrast, in autoreactive T cells that have been tolerized by self-ligands, cross-reactive superagonists may break the tolerant state, resulting in a potentially detrimental autoimmune response. To further understand how peripheral tolerance is maintained against cross-reactive superagonists, we investigated here whether a superagonist peptide can break tolerance induced by high-dose soluble cognate ligand.
To examine the role of cross-reactive superagonist in induction and breaking of peripheral tolerance, we used 1B6 TCR tg mice (29) . These mice express a transgenic TCR from a T cell clone derived from a mouse immunized with the altered peptide (Q144; HSLGKQLGHPDKF), in which glutamine (Q) has replaced the primary TCR contact tryptophan (W) in the autoantigen PLP 139 -151 (HSLGKWLGHPDKF). The 1B6 TCR is cross-reactive with a number of ligands beside the cognate ligand Q144 in a hierarchical fashion. The self autoantigenic peptide PLP 139 -151 (W144) is a weak agonist, whereas Y144 stimulates tg cells more Center for Neurologic Diseases, Harvard Institute of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 strongly than Q144 and the superagonist L144 is a hyperstimulatory ligand (30) .
Using this system, we show here that superagonist L144 can break tolerance to Q144. Although the response is blunted, the cytokine profile was skewed to the anti-inflammatory cytokines IL-4 and IL-10, which may be critical for preventing development of autoimmune disease.
Materials and Methods

Mice
Female SJL mice, 6 -8 wk old, were purchased from The Jackson Laboratory and housed under specific pathogen-free conditions at the Harvard Institutes of Medicine (Boston, MA). 1B6 TCR transgenic mice were generated in our laboratory as described previously (29) . All of the mice were maintained in accordance with guidelines of the Committee on Animals of Harvard Medical School. Female mice, 8 -12 wk old, were used in all the experiments. RAG-2-deficient mice were backcrossed onto the SJL/J background in our laboratory and 1B6 mice were further crossed onto the RAG-2-deficient SJL/J background.
Antigens
Peptide Ags were synthetized by F-moc chemistry and they were Ͼ90% pure. The following peptides were used in this study: proteolipid protein (PLP) 139 -151 (W144) (HSLGKWLGHPDKF), Q144 (HSLGKQLGHP-DKF), Y144 (HSLGKYLGHPDKF), and L144 (HSLGKLLGHPDKF). The relative binding of the PLP analog peptides to I-A s compared with W144 is 0.6 (Q144), 0.6 (Y144), and 0.8 (L144) (29) .
Antibodies
Transgenic 1B6 cells were stained by flow cytometry using a clonotypic biotinylated Ab, 1.16, as previously described (29) . Streptavidin-PE or streptavidin-allophycocyanin was used as a secondary Ab (BD Pharmingen). CD4-allophycocyanin and CD4-FITC were purchased from BD Pharmingen. All of the staining reactions were conducted in 1ϫ PBS containing 2% FCS (Sigma-Aldrich) and acquired using a FACSort flow cytometer (BD Biosciences) and analyzed by FlowJo software (Treestar; Amersham).
CFSE labeling and adoptive transfers
Lymph node cells (LNC) were isolated from tg 1B6 mice and CD3 ϩ cells were enriched by negative selection using mouse T cell enrichment columns (R&D Systems). Ten million T cells were incubated with 1.5 M CFSE in PBS for 5 min at room temperature. The labeled cells were washed once with ice-cold 100% FBS (Sigma-Aldrich) and washed twice with PBS. Five million cells were subsequently transferred i.v. into naive SJL wild-type (wt) mice. For some experiments, unlabeled T cells were transferred to mice.
Induction of anergy and immunizations
Recipient SJL mice were each injected i.p. with high-dose soluble peptides W144 (300 g), Q144 (300 g), Y144 (300 g), or L144 (1, 10, 50, or 100 g) in sterile PBS 2 days after transfer of 1B6 T cells. LNC were isolated 10 days after tolerization and analyzed by flow cytometry. Mice were immunized s.c. with 100 g of Q144, 100 g of Y144, or 1 or 10 g of L144 in CFA 10 days after tolerization. LNC were isolated and analyzed 7 days after immunization. 
Proliferation assays
Cytokine measurement by ELISA
Supernatants obtained from cultures were collected after 48 h of activation and stored at Ϫ70°C until use. Secretion of IL-2, IL-4, IL-10, and IFN-␥ was measured by ELISA. Briefly, cytokine mAbs for IL-2, IL-4, IL-10, and IFN-␥ were coated to 96-well plates at a concentration of 1 g/ml overnight at 4°C. The plates were washed and treated with blocking solution (Kirkegaard & Perry), followed by incubation of culture supernatants overnight at 4°C. The plates were subsequently washed and incubated with their corresponding biotinylated cytokine-detecting mAb (1 g/ml) for 2 h (IL-2: JES6-A112 and JES6-5H4; IL-4: 11B11 and BVD6-24G2; IL-10: JES5-16E3 and SXC-1; IFN-␥: R4-6A2 and XMG1.2). The plates were developed after adding avidin peroxidase and its substrate.
Results
Stimulation with superagonist L144 induces proliferation and alters cytokine production of tg T cells anergized with agonist ligands
To examine the effect of altered peptides on tolerized T cells, an in vivo high-dose tolerance system was set up in which 1B6 tg T cells were transferred into wild-type SJL/J mice (29, 30) . The 1B6 tg mice express a rearranged transgenic TCR which responds to the altered peptide of PLP 139 -151, Q144, in which the tryptophan (W) at 144 was replaced with glutamine (Q) (31) . Besides the cognate ligand Q144, the tg 1B6 cells respond to different ligands in a hierarchical fashion: the PLP 139 -151 peptide (W144) induces a weak proliferative response, whereas agonist Y144 stimulates cells at 1 log less concentration than Q144, and superagonist L144 is able to induce a proliferative response at a 10 5 times lower concentration than the cognate ligand Q144 (29, 30) .
First, we examined whether transferred 1B6 tg T cells retain the potential to respond to different ligands in a hierarchical fashion. Purified T cells from lymph nodes of 1B6 transgenic mice were transferred into naive SJL/J mice. LNC of the recipients were isolated 10 days later, and the proliferative response to different ligands was examined and compared with LNC of naive 1B6 mice. LNC of the recipients were able to proliferate to all four ligands in a hierarchical fashion similar to naive 1B6 tg LNC (Fig. 1A) . In contrast, LNC of naive SJL/J mice have an endogenous response to W144 (PLP 139 -151) (1) and do not respond at all to Q144, Y144, or L144 (data not shown).
Next, we examined whether transferred 1B6 tg T cells can be tolerized by high dose soluble Ag. 1B6 tg T cells were transferred into naive SJL/J mice, and 2 days later, mice were injected with 300 g of soluble Q144 peptide i.p. Ten days after tolerization, LNC of the recipients were isolated and pooled and the proliferative response to the tolerogenic cognate ligand Q144 was determined. As shown in Fig. 1B , the proliferative response to Q144 was greatly reduced in comparison to nontolerized recipients. This decreased proliferative response to Q144 was not due to clonal deletion, because the percentage of tg cells characterized by the double staining with CD4 and a clonotypic mAb 1.16 was similar in tolerized and untolerized mice (Fig. 1C) .
We then examined whether tg T cells, tolerized with the cognate ligand Q144, were able to proliferate in response to weak agonist PLP 139 -151 (W144), agonist Y144, and superagonist L144 peptides. As shown in Fig. 1B , LNC from mice tolerized with Q144 did not proliferate when stimulated with self-peptide W144 in vitro. We concluded that altered peptides, which induce weaker responses than the tolerogenic ligand, could not elicit the proliferation of tolerized T cells. This conclusion was further supported by the finding that if tolerance was induced by Y144, LNC of the recipients were tolerant to all of the ligands weaker than Y144, which included W144, Q144, and Y144 (data not shown). In contrast, superagonist L144 was able to induce proliferation when tg T cells were tolerized with cognate ligand Q144 (Fig. 1B) or agonist Y144 (data not shown). However, this proliferative response was blunted compared with LNC obtained from nontolerized recipients (Fig. 1, A and B) . Moreover, the tolerant tg LNC did not produce IL-2, IFN-␥, IL-4, and IL-10 in response to the tolerogenic ligand (data not shown), but they retained the capacity to secrete IL-2 and IFN-␥ after L144 stimulation (Fig. 1D) . Remarkably, T cells tolerized with Q144 also produced IL-4 in response to L144 stimulation, although no IL-10 was detected. Production of IL-4 was not detected in nontolerized tg T cells, which produced only IL-2 and IFN-␥ upon activation with superagonist (Fig. 1D) . Taken together, the data suggest that tolerized 1B6 T cells were unable to proliferate in response to the tolerogenic and low-affinity ligands, but they responded to superagonist L144, indicating a hierarchy in anergy. However, the response to L144 was altered compared with that of nontolerized cells in that proliferation to L144 was accompanied by IL-4 secretion with a concomitant decrease in IFN-␥ production.
Immunization with superagonist L144 results in expansion of Q144-tolerized T cells in vivo
After confirming that, after tolerization with the cognate ligand Q144, 1B6 tg T cells could still respond to superagonist L144 in vitro, we sought to examine whether exposure to L144 in an inflammatory environment can also break tolerance in vivo. Purified T cells obtained from RAG2-deficient 1B6 transgenic mice were transferred into SJL/J mice. Recipients were tolerized with 300 g of Q144 2 days later and immunized with either 100 g of Q144 or 1 g of superagonist L144 10 days after the induction of tolerance. LNC were isolated 5 days later, and the percentage of 1.16 ϩ CD4 ϩ T cells was determined. Tolerization with Q144 and combined tolerization/immunization with Q144 did not increase the percentage of 1B6 T cells ( Fig. 2A) . In contrast, in mice tolerized with Q144 and immunized with superagonist L144, the percentage of 1B6 tg T cells increased 3-fold, suggesting that immunization induced expansion of tolerized T cells in vivo ( Fig. 2A) . This was further confirmed by studying the expansion of cells in vivo using CFSE. CD3 ϩ cells from 1B6 tg/RAG2-deficient mice were enriched, labeled with CFSE, and transferred into SJL/J mice. Recipient mice were tolerized with 300 g of Q144 2 days later and immunized with either 100 g of Q144 or 1 g of L144 in CFA 10 days later. LNC were isolated 5 days after immunization, and CFSE staining of CD4 ϩ 1.16 ϩ T cells was examined by flow cytometry. A very low-level division of transferred 1B6 T cells was observed following tolerance induction with high-dose Q144 (data not shown). Immunization with 100 g of Q144 in CFA also failed to induce proliferation of tolerized T cells. In contrast, immunization with low dose (1 g) of L144 in CFA induced expansion of tolerized tg T cells (Fig. 2B) . These data suggest that L144 not only elicited a response in Q144-tolerized T cells in vitro, but was also able to induce their proliferation in vivo.
Immunization with superagonist L144 breaks tolerance, but the response is blunted to the tolerogenic peptide in vitro
The in vivo expansion of Q144-tolerized T cells upon immunization with L144 could be due to two reasons: the tg T cells may have responded to the superagonist L144 as evaluated by assessing division in vivo, but still retained unresponsiveness to the tolerogen Q144 ligand. Alternatively, immunization with L144 might in fact break tolerance such that tg T cells lose unresponsiveness to the tolerizing peptide as well. To examine whether immunization with L144 could result in a loss of tolerance in Q144-tolerized 1B6 transgenic T cells, we determined their Q144-specific responses in vitro.
Five million enriched CD3 ϩ 1B6 T cells were transferred to SJL/J mice. Recipient mice were tolerized with 300 g of Q144 2 days later. Ten days after induction of tolerance, mice were immunized with either 100 g of Q144 or 10 g of L144 in CFA. Responses of LNC to Q144 were examined 5 days after immunization in three different experimental systems. We first determined the frequency of 1B6 tg T cells. In cultures stimulated with Q144, the percentage of Q144-tolerized T cells decreased, while immunization with superagonist, L144, overcame tolerance to Q144 and resulted in a 10-fold increase of 1B6 tg T cells in response to Q144 (Fig. 3A) . In addition, LNC of mice tolerized with Q144 and subsequently immunized with L144 were able to proliferate in response to Q144 stimulation. This Q144-specific proliferation was however significantly lower than the response seen in T cells of nontolerized mice immunized with L144 or Q144 (Fig. 3B ). This finding indicated that the immunization with superagonist L144 was able to break tolerance to Q144, but the response to Q144 was blunted compared with the response obtained from nontolerized, L144-immunized recipients. Similar data were obtained when mice were tolerized with Y144 followed with immunization with L144 (data not shown). Finally, the increased percentage of 1B6 ϩ CD4 ϩ T cells in vitro suggested that the blunted proliferation was the response of 1B6 tg T cells and not of endogenously primed SJL/J T cells (Fig. 3A) . To verify this, LNC of Q144-tolerized, L144-immunized recipients were labeled with CFSE and stimulated with 100 g/ml Q144 in vitro for 3 days. We observed that 1.16 ϩ CD4 ϩ tg T cells divided in response to Q144, indicating that immunization with L144 was indeed able to break the unresponsiveness of Q144-tolerized 1B6 tg T cells, although this response was reduced compared with untolerized recipients (Fig. 3C) .
Superagonist breaks T cell tolerance but alters cytokine response
We examined the cytokine response to Q144 stimulation in immunized and tolerized mice. Immunization with Q144 or L144 without tolerization induced a strong IL-2 and IFN-␥ production upon stimulation with Q144 in vitro. In contrast, in LNC cultures of mice tolerized with soluble Q144, the production of IL-2 and IFN-␥ was significantly reduced. Remarkably, immunization of Q144-tolerized mice with L144 induced IL-4 and IL-10 production in LNC. In contrast, LNC from mice that were only tolerized with Q144 did not produce these cytokines (Fig. 4) . Because immunization of mice with L144 did not induce IL-4 and IL-10 either, these cytokines were unlikely to be produced by endogenous non-tg T cells. These data indicated that immunization with superagonist L144 was able to induce a modest response to Q144 in Q144-tolerized 1B6 tg T cells, with preferential production of Th2 cytokines.
High-dose soluble superagonist L144 results in general unresponsiveness of 1B6 tg T cells
Because the superagonist ligand L144 induced responses in tolerized 1B6 tg T cells, and broke tolerance to cognate ligand, we asked whether a high-dose soluble superagonist would induce unresponsiveness to itself and to other 1B6 TCR ligands. Mice that received 1B6 tg T cells were subsequently tolerized with three different concentrations of L144 (3, 10, and 50 g). Proliferation of isolated LNC was determined in response to 1 g/ml L144 10 6 transgenic 1B6 T cells were transferred into wild-type SJL/J mice. Recipient mice were injected with 300 g of soluble Q144 i.p. 2 days later and subsequently immunized with 10 g of L144 in CFA (Qtol/Limm) or left unimmunized (Qtol). LNC were isolated 10 days later and stimulated with 100 g/ml Q144 or medium alone in vitro. The percentage of 1B6 tg cells were determined 3 days later by flow cytometry using a clonotypic mAb (1.16). B, Purified 5 ϫ 10 6 transgenic 1B6 T cells were transferred into wild-type SJL/J mice. Recipient mice were injected with 300 g of Q144 in PBS i.p. 2 days later (Qtol). After 10 days, mice were immunized with either 100 g of the tolerogen Q144 (Qtol/Qimm) or 10 g of L144 in CFA (Qtol/Limm). The proliferative response to the tolerogen Q144 was determined 5 days later and was compared with proliferation of cells from recipients, which were not tolerized with Q144 but were immunized with 100 g of Q144 (Qimm) or 10 g of L144 (Limm). C, Purified 5 ϫ 10 6 1B6 T cells were transferred into wildtype SJL/J mice. Recipient mice were left untreated or injected with 300 g of Q144 in PBS i.p. 2 days later. After 10 days, mice were immunized with 10 g of L144 in CFA or left unimmunized. LNC were isolated after 5 days, labeled with CFSE, and restimulated with tolerogen Q144 (100 g/ ml). Cell divisions were assessed in 1.16 ϩ CD4 ϩ gated cells by flow cytometry. Open histograms indicate cell divisions of tg T cells stimulated with Q144, whereas filled histograms indicate unstimulated cultured tg T cells. days later. Even the lowest dose of soluble L144 was able to induce a reduction of the proliferative response to L144, which was more pronounced with increasing doses of tolerogen (data not shown).
As described, L144 was able to break unresponsiveness induced by the weaker agonists Q144 or Y144, and we now asked whether L144-tolerized 1B6 tg T cells can respond to Q144 and Y144. Recipient SJL mice were tolerized with 10 g of soluble L144, and LNC were restimulated with W144, Q144, Y144, and L144 peptides in vitro 10 days later. None of the tested peptides induced proliferation of 1B6 tg T cells (Fig. 5A) . Similar results were obtained by tolerization with 100 g of soluble L144 (data not shown). These data demonstrate that, once tolerance was induced by superagonist L144, LNC were unable to proliferate to any tested 1B6 TCR ligands, not even the superagonist L144. We next asked whether this unresponsiveness could be overcome by adding exogenous IL-2 to the T cell cultures, as demonstrated in the classical anergy experiments (17) . However, addition of exogenous recombinant human IL-2 to the cultures was unable to break unresponsiveness induced by tolerization with L144 (Fig. 5B, left  panel) . In contrast, T cells proliferated when stimulated with increasing dosages of PMA (4 -20 ng/ml) and ionomycin (0.08 -0.4 g/ml), suggesting that signaling events distal of the TCR were retained and not directly involved in L144-induced tolerance of 1B6 T cells (Fig. 5B, right panel) .
Next, we examined whether LNC tolerized with superagonist were able to produce cytokines in response to different ligands. Mice were tolerized with 1 or 50 g of soluble L144 or immunized with 1 or 10 g of L144 in CFA. LNC were restimulated 10 days later with 100 g/ml W144, Q144, and Y144 or with 1 g/ml L144. Secretion of IL-2, IL-4, IL-10, and IFN-␥ was measured by ELISA in supernatants after 48 h. As shown in Fig. 5C , secretion of IL-2 and IFN-␥ was completely abrogated in response to all tested TCR ligands following tolerization with the L144 peptide. In contrast, immunization with L144 increased the IL-2 and IFN-␥ production of 1B6 tg T cells in response to Q144, Y144, and L144 in a dose-dependent and hierarchical manner. IL-4 and IL-10 cytokines were not detected. Taken together, although superagonist L144 was able to induce an altered hierarchical cytokine response in 1B6 tg T cells tolerized with cognate peptide, once these T cells were tolerized with L144, they were unable to produce Th1 or Th2 cytokines in response to any of the 1B6 TCR ligands tested.
Furthermore, tolerization with L144 resulted in an increased in vivo percentage (Fig. 1C) and cycling (data not shown) of tg 1.16 ϩ CD4 ϩ T cells, indicating proliferation. These data suggested that 1B6 tg T cells were able to divide in response to tolerogen L144 in vivo, but that they were unresponsive when further activated on day 10 ex vivo. This might suggest that the global unresponsiveness induced by L144 requires active cell division by T cells (29) . 6 1B6 T cells were transferred into wild-type SJL/J mice. Recipient mice were injected with either PBS or 300 g of Q144 in PBS i.p. 2 days later (Qtol). After 10 days, mice were immunized with either 100 g of Q144 (Qtol/Qimm) or 10 g of L144 in CFA (Qtol/Limm). As control, untolerized recipient mice were immunized with 100 g of Q144 (Qimm) or 10 g of L144 (Limm). Cells were isolated 5 days later and stimulated with 10 g/ml (f) or 100 g/ml (Ⅺ) Q144. The cytokine response to Q144 was determined in supernatants of LNC cultures. 6 1B6 T cells were transferred into wild-type SJL/J mice. Recipient mice were injected with either L144 (1 or 10 g) in CFA (immunized), PBS (untolerized), or soluble L144 (50 or 100 g) (tolerized) 2 days later. Cytokine production was examined 10 days later in supernatants of LNC cultures stimulated with 100 g/ml W144, Q144, or Y144 or 1 g/ml L144 for 48 h.
Discussion
How tolerance to self-Ags is sustained, when responses to unrelated foreign Ags can activate autoreactive T cells, is one of the basic questions regarding autoimmunity. One possible mechanism is that tolerance to self results in unresponsiveness to foreign Ags (32) . We have recently shown that a cross-reactive superagonist induced unresponsiveness of self-specific, untolerized T cells (29) .
In this study, we demonstrated how tolerance is maintained or broken by the same superagonist, L144, if the self-specific T cells had been already tolerized by the cognate peptide. We observed that, although superagonist could break tolerance to the cognate ligand, an anti-inflammatory cytokine production was induced.
Several studies have previously addressed whether tolerance to cognate peptides could be broken. Those data suggested that breaking tolerance involves stimulation of low-affinity clones, which escape tolerance induction (33) (34) (35) . Recently, it has been suggested that anergy was not reversed on the clonal level, rather, breaking tolerance involved the activation of T cells with low affinity for the tolerogen and high affinity for the heteroclitic Ag (36, 37) . In contrast, our data imply that superagonist L144 reversed tolerance at a clonal level. However, L144 is a superagonist peptide, which is capable of inducing maximal proliferation at 7 logs lower Ag concentration than tolerogenic ligand Q144. The agonist ligand Y144, which elicits responses at a 10-fold lower concentration than Q144, was unable to induce a response in Q144-tolerized tg T cells; this is consistent with previous reports (36) . Our data suggest that a very strong stimulus provided by a superagonist is needed to reverse tolerance at the clonal level. Because the reversal of tolerance was also observed in tg 1B6 cells on the RAG2-deficient background, it excludes the possibility that untolerized low-avidity T cells expressing endogenous TCR ␣-chains, coupled with the tg ␤-chain, responded to L144.
Furthermore, the reversal of clonal tolerance was characterized by the production of the Th2 cytokines IL-4 and IL-10 in response to subsequent activation with the cognate ligand. We observed the production of anti-inflammatory cytokines in two experimental systems. First, transgenic T cells tolerant to Q144 responded to the superagonist with the production of IL-4 in vitro. This response was similar to the previously observed Th2 cytokine production by T cells anergized with high-affinity ligand (38) . In addition, in mice tolerized with Q144, immunization with L144 was able to abrogate tolerance and elicit a T cell response to Q144 in vitro. However, responding 1B6 T cells also produced IL-4 and IL-10 and significantly less IFN-␥ and IL-2 compared with untolerized mice. It has been shown previously that chronic Ag stimulus may result in anergy as well as in IL-10 production in vivo (39 -41) . The phenotype of 1B6 T cells after breaking tolerance was very similar to these previously described anergic T cells: they produced IL-10, but low levels of IL-2 and IFN-␥ in response to Q144 restimulation. This blunted and deviated immune response indicates that superantigen L144 does not restore the cognate response to Q144 but elicits an "altered" response in the tolerized cells, similar to that induced by repeated antigenic stimulation (39 -41) . It is likely that the stimulus provided by superagonist is weak in these tolerized cells and induces Th2 responses, which require low activating signals for activation similar to that induced by a suboptimal antigenic stimulation. Numerous studies have shown that a suboptimal stimulus provided by structural alterations (42, 43) or by changing the amount of an antigenic ligand (43) (44) (45) (46) (47) affects the polarized differentiation into Th1/Th2 effector cells such that suboptimal stimulus favors the production of Th2 cytokines. We may also speculate that IL-10 and IL-4 induced by L144 may be required for maintaining tolerance and suppressing inflammatory cross-reactive Th1 autoimmune responses (48 -50) . Taken together, our data suggest two main mechanisms that may prevent a detrimental autoreactive T cell response induced by a cross-reactive superagonist: 1) if autoreactive T cells are not tolerized, they may become unresponsive to the cognate self-ligand upon encounter with the superagonist, as we have described previously (29) . 2) If T cells are already tolerized to self-Ag, a cross-reactive superagonist may induce a blunted response to the tolerizing ligand and production of anti-inflammatory Th2 cytokines. This altered response may counterbalance the "broken tolerance."
Because we observed that superagonist L144 could break unresponsiveness to cognate ligand Q144, we examined whether the superagonist itself is able to induce tolerance. In contrast to our expectations, we found that high-dose soluble L144 induced a general unresponsiveness to all tested 1B6 TCR ligands. Considering that L144 could elicit a response in T cells tolerized with Q144, but no response could be induced with any cross-reactive ligands when 1B6 cells were tolerized with L144, this implies that tolerance was induced in a hierarchical fashion. The in vivo expansion followed by in vitro unresponsiveness induced by L144 tolerization was very similar to tolerance induced by 50 g of L144 immunization (29) . It is possible that unresponsiveness induced by either highdose soluble L144 (50 -100 g) or immunization with L144 in CFA (50 g) may be mediated by similar mechanisms, because in both cases: 1) exogenous IL-2 failed to rescue the unresponsiveness; 2) the responses downstream of the TCR induced by PMA/ ionomycin were retained; and 3) the L144-treated cells were accompanied with up-regulation of CD5 in vivo, which may be important in this kind of unresponsiveness as a negative signal (data not shown). It is also possible that soluble L144 might invoke different mechanisms for the induction of tolerance when compared with soluble Q144. In summary, if 1B6 tg T cells were not tolerized, the cross-reactive superagonist L144 induced Th1 cytokine production in naive T cells in vitro (29) . If 1B6 cells were tolerized to the cognate ligand Q144, superagonist L144 elicited an altered but blunted response in vitro. Similarly, although immunization with low-dose superagonist was able to break tolerance to the cognate ligand Q144, this response was blunted and characterized by production of Th2 cytokines. This blunted response with altered cytokine production may provide a mechanism by which a cross-reactive high-affinity ligand is not able to induce a pathogenic autoimmune response in tolerized self-reactive T cell clones.
